September 11, 2024 10:15 AM EDT : Baird 2024 Global Healthcare Conference Post author:Allogene Therapeutics Events Post published:September 11, 2024 Post category:Uncategorized Continue ReadingSeptember 11, 2024 10:15 AM EDT : Baird 2024 Global Healthcare Conference
ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy Post author:andrewkaretas Post published:July 15, 2024 Post category:Uncategorized Continue ReadingALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑cel) in Patients With Large B‑cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy
FT US Pharma and Biotech Summit Post author:andrewkaretas Post published:June 12, 2024 Post category:Perspectives/Uncategorized Continue ReadingFT US Pharma and Biotech Summit
Test Post author:andrewkaretas Post published:October 5, 2021 Post category:Uncategorized Continue ReadingTest
